Development Pathway / Pipeline

Innovative medicines from currently available products.

Madeira will utilize the 505(b)(2) approval pathway for our drug development programs.  The 505(b)(2) process relies in part on the FDA’s findings for a previously approved drug—shortcutting IND approval by years and saving millions of dollars.

Madeira Therapeutics’ executive team and board of advisors are industry experts in drug development, pharmaceuticals and 505(b)(2) applications.

505(b)(2) Pathway